Authored By: Sarah
11 Jul 2024

 Sarcoma Therapeutics Market Size to grow by USD 1110.8 million between 2024-2028

According to a research report “ Sarcoma Therapeutics Market” by Type (Soft tissue sarcoma, Osteosarcoma) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1110.8 million, at a CAGR of  8.51% during the forecast period. The global sarcoma therapeutics market has experienced a notable growth in patient assistance programs due to the escalating costs associated with oncology treatments. The substantial expense of oncology therapeutics poses a significant challenge for patients, as these treatments represent a substantial portion of overall healthcare costs. In response to this issue, governments and pharmaceutical vendors have introduced various patient assistance programs to alleviate the financial burden on patients. For example, the US government has implemented initiatives like the Patient Protection and Affordable Care Act, commonly referred to as Obamacare, to mitigate the cost burden for patients.

Browse market data tables, figures, and in-depth TOC on “Sarcoma Therapeutics Market” by Type (Soft tissue sarcoma, Osteosarcoma) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the Soft tissue sarcoma segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

The sarcoma therapeutics market represents a significant business opportunity for pharmaceutical companies, driven by the high unmet medical need for effective treatments. This niche market is characterized by a growing pipeline of innovative therapies, including targeted agents and immunotherapies, which offer promising advances in sarcoma treatment. Market growth is further fueled by increasing incidence rates and rising healthcare expenditures. Pharmaceutical companies are investing heavily in research and development to bring new, differentiated therapies to market and capture a share of this lucrative market.

North America is forecasted to hold the largest market size by region in 2024

The sarcoma therapeutics market represents a significant business opportunity for pharmaceutical companies, driven by the high unmet medical need for effective treatments. Sarcomas, a diverse group of malignant tumors, often exhibit aggressive growth and limited treatment options. Market growth is expected due to the pipeline of novel targeted therapies, immunotherapies, and combination treatments. Companies investing in sarcoma therapeutics research and development stand to gain from potential market expansion and improved patient outcomes.

The Sarcoma Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Adaptimmune Therapeutics plc
  • Advenchen Laboratories LLC
  • Agenus Inc.
  • Agios Inc.
  • Athenex Inc.
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Ipsen Pharma
  • Johnson and Johnson Services Inc.
  • Karyopharm Therapeutics Inc.
  • LadRx Corp.
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • PharmaMar SA
  • SillaJen Co. Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Sarcoma Therapeutics Market is witnessing a rising demand due to the increasing incidence of sarcoma, a type of cancer that affects the soft tissues such as cartilage, blood vessels, fibrous tissue, and bone. Skin cancers, including melanoma and non-melanoma, are the most common type of cancer, but sarcomas account for only 1% of all cancer cases. However, the number of sarcoma cases is on the rise, leading to a significant increase in deaths. The diagnosis and treatment of sarcoma have seen technological advancements, including automated processes for diagnostic methods and the development of novel drugs. The developmental pipeline for sarcoma drugs is robust, with several companies focusing on bringing new treatments to market. The use of low-cost therapeutics is also gaining importance as a way to make sarcoma treatment more accessible to a larger patient population. Raising awareness about sarcoma and its symptoms is crucial for early detection and effective treatment. The market for sarcoma therapeutics is expected to grow significantly in the coming years.

Market Research Overview

Title: Sarcoma Therapeutics Market: Overview, Rising Incidence, Technological Advancements, and Treatment Landscape Sarcoma, a type of cancer that develops in the soft tissues such as muscles, cartilage, fibrous tissue, fat, blood vessels, tendons, nerves, and bones, is a rare and heterogeneous group of malignancies. The rising incidence of skin cancers, including sarcomas, and the high risk of death make this a critical area of focus for the healthcare industry. The diagnosis and treatment of sarcomas involve various modalities, including surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and gene therapy. Technological advancements in the field have led to the development of novel drugs, automated processes, patient-centric solutions, and supply chain optimization. The global sarcoma therapeutics market is segmented by region, type of sarcoma (rhabdomyosarcoma, osteosarcoma, liposarcoma, etc.), treatment type (surgery, chemotherapy, targeted therapy, immunotherapy, etc.), and regulatory framework. The market is driven by factors such as increased sarcoma cases, government efforts, clinical trials, strategic alliances, and public awareness. The cost of treatment and reimbursement are significant challenges in the sarcoma therapeutics market. Health insurance and medical expenses are major concerns for patients and healthcare providers. Monoclonal antibodies, small molecules, gene therapy, cancer vaccines, checkpoint inhibitors, and other immuno-oncology agents are some of the therapeutic modalities under development. The sarcoma drugs market is highly competitive, with academic organizations, pharmaceutical firms, and government efforts collaborating to advance the clinical pipeline. The market is also witnessing partnerships and collaborations, combination treatments, targeted medicines, and personalized medicine techniques. Risk factors for sarcoma include age groups, chemical exposure, lymph system issues, genetic mutation, and malignant bone sarcomas. The subtypes of sarcoma include histological subtypes, such as those affecting muscles, nerves, fat, and bones. The treatment landscape for sarcoma is evolving rapidly, with online pharmacies, retail pharmacies, and hospital pharmacies offering various treatment options. Public awareness and data sharing are crucial for improving patient outcomes and reducing deaths from sarcoma. A collaborative atmosphere and remote care through telemedicine are also gaining popularity in the sarcoma therapeutics market.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio